To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
Human Alpha-Synuclein Mouse*
Mouse Model
Homozygous knockout of endogenous wild type mouse alpha-synuclein, with BAC expression of the full human alpha synuclein gene and 34kb of its upstream region. Model was generated and deposited by Robert Nussbaum at University of California San Francisco through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:010710
PINK1 Knockout Mouse*
Mouse Model
PINK1 knockout mice with exons 4 through 7 deleted, producing a nonsense mutation at the start of exon 8 due to a reading frame shift. Model was generated and deposited by Jie Shen at Harvard Medical School Brigham and Women’s Hospital through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:017946
LRRK2 Knockout Mouse*
Mouse Model
Homozygous LRRK2 knockout mice with the promoter and exon 1 deleted. Model was generated and deposited by Jie Shen at Harvard Medical School Brigham and Women’s Hospital through the MJFF Sponsored Tools Program (available through cryorecovery).
ATP13A2 Knockout Mouse*
Mouse Model
Mice carrying a Atp13a2 mutation resulting in disruption of exons 12 through 15 and a portion of exon 16. Model was generated and deposited by Patrick Schultheis at Northern Kentucky University through the MJFF Sponsored Tools Program (available through cryorecovery). RRID:IMSR_JAX:021914
iPLA2beta Knockout Mouse*
Mouse Model
Mice carrying a Pla2g6 mutation resulting replacement of exon 2 by a NEO cassette. Model was generated and deposited by Zemin Yao at University of Ottawa through the MJFF Sponsored Tools Program (available through cryorecovery). RRID:IMSR_JAX:023542
AAV5-CBA-Alpha-Synuclein
Viral Vector
Viral vector (AAV5 serotype) encoding wild-type alpha-synuclein. Produced by the UNC Vector Core. AAV5-CBA-eGFP available as a control in Control section.
Characterization data for this viral vector can be found here.
LoxP LRRK2 Mouse*
Mouse Model
Mice possessing loxP sites on either side of the exon 41 of the LRRK2 gene. Model was generated and deposited by Heather Melrose at Mayo Clinic College of Medicine through the MJFF Sponsored Tools Program (available through cryorecovery). RRID:IMSR_JAX:024469
FLAG LRRK2 G2019S Mouse*
Mouse Model
Mice expressing FLAG-LRRK2-G2019S transgene directed by the endogenous LRRK2 promoter/enhancer regions on the BAC transgene. Model was generated and deposited by Zhenyu Yue at Mount Sinai School of Medicine through the MJFF Sponsored Tools Program (available through cryorecovery). RRID:IMSR_JAX:012467
LRRK2 G2019S Mouse*
Mouse Model
Transgenic mice expressing full length LRRK2 with G2019S mutation driven by CMV enhancer and PDGFB promoter/enhancer elements. Model was generated and deposited by Darren Moore at Van Andel Research Institute and Valina Dawson at Johns Hopkins University through the MJFF Sponsored Tools Program (available through cryorecovery). RRID:IMSR_JAX:016575
LRRK2 R1441C Mouse*
Mouse Model
Transgenic mice expressing full length LRRK2 with R1441C mutation driven by CMV enhancer and PDGFB promoter/enhancer elements. Model was generated and deposited by Darren Moore at Van Andel Research Institute and Valina Dawson at Johns Hopkins University through the MJFF Sponsored Tools Program (available through cryorecovery). RRID:IMSR_JAX:016576
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic